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Key points 
 
1. Early thrombolytic treatment with a bispecific inhibitor against TAFI and PAI-1 is effective 
without exogenous tPA 
2. Even at the highest dose tested, the bispecific inhibitor against TAFI and PAI-1 does not 
prolong bleeding time.  
 
Abstract 
Circulating thrombin-activatable fibrinolysis inhibitor (TAFI) and plasminogen activator inhibitor-1 
(PAI-1) are causal factors for thrombolytic failure. Therefore, we evaluated an antibody-engineered 
bispecific inhibitor against TAFI and PAI-1 (heterodimer diabody, Db-TCK26D6x33H1F7) in several 
mouse models of thrombosis and stroke. Prophylactic administration of the diabody (0.8mg/kg) in a 
thromboplastin-induced model of thromboembolism led to decreased lung fibrin deposition. In a 
model of cerebral ischemia/reperfusion, diabody administration (0.8mg/kg, 1h post occlusion) led to 
a mitigated cerebral injury with a 2.3-fold reduced lesion and improved functional outcomes. In a 
mouse model of thrombin-induced middle cerebral artery occlusion (MCAo), the efficacy of the 
diabody was compared to the standard thrombolytic treatment with recombinant tissue-type 
plasminogen activator (tPA). Early administration of diabody (0.8mg/kg, 20min post occlusion) 
caused a 2-fold decrease in brain lesion size, whereas that of tPA (10mg/kg) had a much smaller 
effect. Delayed administration of diabody or tPA (90min post occlusion) had no effect on lesion size, 
whereas the combined administration of diabody with tPA caused a 1.7-fold decrease in lesion size. 
In contrast to tPA, the diabody did not increase accumulative bleeding. In conclusion, administration 
of a bispecific inhibitor against TAFI and PAI-1 results in a prominent profibrinolytic effect in mice 
without increased bleeding.   
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Introduction  
 
Plasminogen activators are the only thrombolytic agents approved to rapidly revascularize a 
thrombosed vessel. Reperfusion of the ischemia-affected organ leads to an improved outcome in 
patients when applied within the first hours after ischemic onset.
1
 Despite this evidence-based 
beneficial effect, current thrombolytic agents remain widely underutilized due to life-threatening 
side-effects, such as cerebral hemorrhages and possible neurotoxicity.
2,3
 For acute ischemic stroke, in 
particular, the only licensed treatment option consists of a high systemic dose of recombinant tissue-
type plasminogen activator (tPA), which is actually given to less than 10% of the patients. Therefore, 
there is an unmet clinical need to explore novel therapeutic avenues to enhance fibrinolysis without 
plasminogen activator-associated adverse effects. Endogenous intravascular fibrinolysis is driven 
upon the release of tPA from the endothelium, which in turn enzymatically activates plasminogen 
into the fibrin-degrading enzyme, plasmin.
4
 This activation step is attenuated by circulating 
thrombin-activatable fibrinolysis inhibitor (TAFI) and plasminogen activator inhibitor-1 (PAI-1). 
Activated TAFI (TAFIa, encoded by the CPB2 gene) eliminates C-terminal Lys exposed on partially 
degraded fibrin which ultimately leads to a diminished efficiency and localization of plasminogen 
activation by t-PA.
5
 PAI-1 belongs to the serine protease inhibitor (serpin) superfamily and is the 
primary inhibitor of tPA. The active form of PAI-1 can irreversibly neutralize the activity of its target 
serine protease by forming a 1:1 stoichiometric covalent complex, accompanied by deformation of 
the catalytic triad of the serine protease.
6
  
Accordingly, elevated plasma levels of TAFI and/or PAI-1 instigate an increased risk for thrombotic 
disorders (e.g. venous thromboembolism,
7
 acute ischemic stroke
8
 and acute myocardial infarction
9,10
) 
and cause thrombolytic failure.
11,12
 A considerable number of studies using animal thrombosis 
models have demonstrated a beneficial effect of TAFI or PAI-1 as drug targets,
13
 but no study has yet 
shown thrombolytic superiority over plasminogen activators.
14,15
 We postulate that single targeting 
of the anti-fibrinolytic system does not suffice for robust thrombolysis. Since TAFI and PAI-1 act 
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complementary at the fibrin surface,
16
 we hypothesized that dual TAFI/PAI-1 targeting would allow 
efficient thrombolysis at safer systemic drug levels.  
Highly specific monoclonal antibodies (MA) against TAFI and PAI-1 are available and have been 
previously validated in vivo.
17-19
 MA-TCK26D6 modulates TAFI/TAFIa by impairing activation mediated 
by thrombin and plasmin, however it does not block the stronger activator, 
thrombin/thrombomodulin.
17
 Interestingly this antibody also prevents the specific interaction of 
TAFIa on fibrin, but not on the other small pro-inflammatory substrates of TAFIa.
20
 MA-33H1F7 
converts the active form of PAI-1 to a substrate for tPA, leading to the irreversible cleavage of PAI-
1.
21
 TAFI and PAI-1 both act in the vicinity of a fibrin clot, making simultaneous targeting of the two 
antigens through one protein a feasible and potentially safer strategy. Previously, a corresponding 
small recombinantly engineered bispecific antibody, a diabody, was developed to target TAFI and 
PAI-1 simultaneously and was designated as Db-TCK26D6x33H1F7.
22
 In a thromboelastometric assay, 
we confirmed that simultaneous inhibition of TAFI and PAI-1 causes an enhancement of in vitro 
fibrinolysis in human and mouse blood.
22
  
In the present study, Db-TCK26D6x33H1F7 was used to evaluate the concept of dual TAFI/PAI-1 
inhibition in models of thromboembolism and stroke. The thromboprophylactic capacity of the 
diabody was evaluated in a well-established mouse model of venous thromboembolism.
17,18,23,24
 In 
addition, the effect of the diabody on brain ischemia and reperfusion injury was assessed in a 
mechanical transient middle cerebral artery occlusion (MCAo) model in which brain lesion and 
neurological/motor outcome were measured. Furthermore, the profibrinolytic capacity was 
evaluated in two stroke models where in situ clots are induced in the vascular lumen of the middle 
cerebral artery (MCA) via a thrombin- and a FeCl
3
-induced MCAo model. The goal was to compare 
the efficacy of the diabody vs. the standard thrombolytic treatment with tPA post thrombus 
formation. Finally, safety regarding potential bleeding risks was evaluated.  
  5 
Methods    
A detailed description of the methods is provided in the Online Data Supplement. 
Animals 
Thromboplastin-induced thromboembolism, pharmacokinetics and tail bleeding assay were 
performed on female SWISS mice (18-22 g, Janvier, France). Mechanical transient middle cerebral 
artery occlusion (tMCAo) was performed on male/female C57BL/6J mice (16-20 g for females and 20-
24 g for male, The Jackson laboratory). Thrombotic middle cerebral artery occlusion (MCAo) was 
performed on male SWISS mice (30-35 g, Janvier). Experiments were performed in accordance with 
local ethical laws and the local ethical committees (cfr. Online Data supplement for details) and 
European Communities Council Directives of November 24, 1986 (86/609/EEC) guidelines for the 
care and use of laboratory animals. All experiments were performed following the ARRIVE guidelines 
(www.nc3rs.org.uk), including randomization of treatment as well as surgery and analysis blind to the 
treatment.  
Venous thromboembolism model 
Thromboplastin-induced thromboembolism was performed as described previously
17
 with slight 
modifications. Endotoxemia was induced in overnight fasted non-anesthetized mice by 
intraperitoneal injection of lipopolysaccharide (LPS; 0.5mg/kg) from Escherichia coli serotype 026:B6 
(Sigma-Aldrich, St. Louis, MO, USA) 3 h prior to the start of the experiment. Then, diabody (0.2 mg/kg 
or 0.8mg/kg) or vehicle (isotonic saline) was intravenously (IV) administered via tail vein injection in 
endotoxemic mice. Five min post treatment, thromboembolism was induced by IV injection of 
thromboplastin (corresponding to a dose of 2.5µg/kg tissue factor). Fibrin deposition in lungs was 
quantified 15 min post thromboplastin injection as described previously (see supplement).
17
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Mechanical transient MCAo (tMCAo) 
Surgical procedures and treatments 
Mechanical transient MCAo (tMCAo) was performed as described previously according to the 
monofilament method.
25
 The intraluminal suture was left in situ during 60 min. Then animals were 
reanesthetized, and the occluding monofilament was withdrawn to allow reperfusion. Immediately 
after reperfusion, diabody (0.8mg/kg) or vehicle (PBS) was administered IV.  
Neurological tests 
24 h post occlusion, mice were subjected to the modified Bederson test
26
 and the grip test
27
 to assess 
global neurological function and motor function, respectively (see supplement).  
Lesion quantification and cerebral fibrinogen 
24 h post occlusion, mice were euthanized to quantify lesion volumes through staining with 2% 2,3,5-
triphenyl-tetrazolium chloride. Cerebral fibrin(ogen) was determined as described in the 
supplemental section “protein extraction and Western blot analysis”. 
 
Thrombotic (thrombin-induced) MCAo 
Surgical procedure and treatments 
Deeply anesthetized mice by inhalation of 5% isoflurane/oxygen mixture were placed on a 
stereotaxic device and were maintained under anesthesia by inhalation of 2% isoflurane/oxygen 
mixture during surgical procedures. Body temperature was maintained at 37°C with a thermostat-
controlled heating pad throughout the whole procedure. Right middle cerebral artery (MCA) was 
exposed by craniectomy. In situ occlusion of the MCA was performed by micro-injection of murine 
alpha-thrombin (1 IU, Kordia, Leiden, The Netherlands) into the MCA
28
 and time of occlusion was 
determined by Laser Doppler flowmetry. Diabody (Db) or vehicle (PBS) was injected IV via a tail vein 
catheter at certain time points post occlusion: an early (20 min), intermediate (90 min) or late (240 
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min) time point. Five min after diabody or vehicle administration, tPA (10mg/kg) or saline was 
administered IV (10% as bolus and 90% infused over 40 min).   
Magnetic resonance imaging (MRI) analysis 
MRI was performed at 24 h post occlusion on a Pharmascan 7 T/12 cm system using surface coils 
(Bruker Biospin, Wissembourg, France). Brain lesion volume was determined by T2-weighted MRI 
(Multi-Slice Multi-Echo (MSME) sequence: TR/TE 2500 ms/51 ms
29
), the angiographic scoring of the 
MCA (0= occlusion, 1= partial recanalization and 2= complete recanalization) was determined by MR 
angiography (MRA) (2D-TOF sequences 
30
) and cerebral hemorrhages were detected by T2*-weighted 
MRI (Fast Low Angle Shot sequence: TR/TE 350 ms/ 6 ms). Mice with a lesion volume <3 mm
3
 were 
excluded (no mice were excluded from thrombin-induced MCAo experiments). 
 
 
 
Tail bleeding assay 
Mouse tail vein bleeding times and hemoglobin loss were determined with a tail-clipping assay, as 
described previously (see supplement).
31
  
 
Statistical analysis 
All quantitative data are presented as mean and standard error of mean (SEM). Statistical analysis 
was performed with GraphPad Prism Version 5 (GraphPad Software) (see supplement). P-values less 
than 0.05 were considered significant.  
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Results  
Characterization of the profibrinolytic effect of diabody in a model of venous thromboembolism 
In a model of thromboplastin-induced thromboembolism, which is well-established for the 
evaluation of profibrinolytic agents,
17,18,23,32
 the diabody was tested in order to determine an 
effective dosage. Because of the extremely low baseline levels of PAI-1 in mice, endotoxemic mice 
were used in this type of acute model to obtain a potential contributing effect of PAI-1 inhibition. 
Previously it was reported that under the given conditions, endotoxemic mice had an increased PAI-1 
plasma level of 112±30 ng/mL.
33
 In this study, the plasma level of TAFI was also measured under 
endotoxemic conditions and was found to be 6.5±0.4 µg/mL (n=3). An initial dosage of 0.2 mg/kg was 
administered IV to obtain a circulating concentration of diabody theoretically equimolar to TAFI [TAFI 
plasma level (µg/mL) x plasma volume/body weight (mL/mg) x correction Mw: 6.5 µg/mL x 0.030 
mL/mg x 58 kDa /56 kDa= 0.2mg/kg]. At 0.2 mg/kg diabody, thromboplastin-induced fibrin 
deposition in lungs was reduced, however not to a significant degree. With a higher dosage of 0.8 
mg/kg diabody, however, fibrin deposition in the lungs was maximally reduced (94% reduction; 
Figure 1; p<0.01 vs. vehicle, n=10 mice/group). In fact, 5 min post administration of 0.8 mg/kg 
diabody, the plasma level was 6.6±0.2 µg/mL diabody (n=3, Supplemental figure S2), which is 
consistent with the rapid initial clearance (t
1/2α
) of a diabody.
34
 Thus, administration of diabody at 0.8 
mg/kg results in an approximately equimolar concentration to TAFI shortly after injection. The 
diabody was used at a dose of 0.8 mg/kg in further experiments, except for the thrombolysis 
experiments on FeCl
3
-induced thrombi (Supplemental figure S3), which are more resistant to 
fibrinolysis. 
 
Profibrinolytic effect of diabody on cerebral ischemia/reperfusion injury 
A mechanical tMCAo model was used to assess the effect of diabody on cerebral 
ischemia/reperfusion injury when administered 1 h post occlusion. This model typically yields large 
lesion volumes in untreated mice which have measurable neurological/motor defects. Experiments 
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on the pharmacokinetics of the diabody showed that its circulating half-life (t
1/2β
) is 121 min 
(Supplemental figure S2), which allows its administration by a single bolus. 24 h post occlusion, mice 
treated with diabody (0.8 mg/kg) exhibited significantly reduced lesion volumes (Figures 2A-B; 
p<0.01; n=10-12 mice/group) and concomitantly improved neurological (Figure 2C; p<0.05; n=10-12 
mice/group) and motor scores (Figure 2D; p<0.01; n=10-12 mice/group). In addition, western blot 
analysis revealed that the diabody effectively reduced massive fibrin deposition induced by 
reperfusion injury by at least 2-fold (Figures 2E-F; p<0.05; n=4 mice/group).  
Thrombolytic effect of the diabody on fibrin-rich clots in a model of thrombin-induced stroke 
A model of thromboembolic stroke by local thrombin injection was used in which clots are rich in 
fibrin and thus susceptible to be thrombolysed by tPA when administered early post clot onset, i.e. 
20 min post occlusion. The efficacy of the diabody was compared to that of tPA, the current 
thrombolytic agent. In order to mimic the clinical procedure of thrombolysis, the administration of 
tPA was performed by an initial bolus of 10% volume followed by 90% infusion during 40 min 
because of the short half-life of circulating tPA (~ 5 min
35
). 24 h post occlusion, complete 
recanalization of the arterial lumen occurred in all groups including the vehicle group (median 
angiographic score=2). Lesion volume was reduced by early administration of tPA, however this 
reduction was not statistically significant (37±13 mm
3
 vs. 26±12 mm
3
; Figure 3A; p=0.203; n=6-8 
mice/group). In contrast, early diabody administration (0.8 mg/kg), regardless of the co-
administration of tPA, substantially reduced lesion volume at 24 h (15±4 mm
3
 for diabody and 15±8 
mm
3
 for diabody + tPA; p<0.01 and p<0.05 vs. vehicle respectively; n=6-8 mice/group; Figure 3A).  
When delaying the treatments to a clinically more relevant time point, e.g. 90 min post occlusion 
(intermediate time point),
36
 complete recanalization was also observed at 24 h post occlusion in all 
treatment groups (median angiographic score= 2). Intermediately delayed administration of diabody 
nor infusion of tPA had any beneficial effect on the lesion volume (25±3 mm
3
 (vehicle) vs. 24±3 mm
3
 
(tPA) vs. 21±4 mm
3
 
(Db); Figure 3B; n=9-10 mice/group). However, at the same treatment time point 
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diabody administration prior to tPA infusion resulted in a significantly reduced lesion volume (15±2 
mm
3
 (Db+tPA); p<0.05 vs. vehicle; n=10 mice/group; Figure 3B). 
None of the treatments had an effect on lesion sizes in this model when administered at 240 min 
post occlusion (late time point, Figure 3C).  
Assessment of bleeding  
Tail bleeding experiments were performed to compare the effects of an IV injection of tPA at two 
different doses: the dose equivalent to that used in clinical practice for humans (1 mg/kg) and to that 
typically used in mice (10 mg/kg). Diabody was injected at 0.8 mg/kg and 3.6 mg/kg. IV 
administration of diabody up to 3.6 mg/kg did not alter tail bleeding time or accumulative 
hemoglobin loss after 60 min tail incubation, whereas both doses of tPA prolonged bleeding time and 
increased hemoglobin loss (Figure 4A-B; n=9-10 mice/group). Co-administration of diabody (0.8 
mg/kg) and tPA (10 mg/kg), the treatment regimen tested in the thrombin-mediated MCAo model, 
did not further increase the tail bleeding time nor hemoglobin loss compared to tPA administration 
alone.  
Alternatively, no cerebral hemorrhages were observed in either mechanical or thrombotic MCAo 
stroke models after any treatment. 
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Discussion  
Based on a considerable amount of clinical data, elevated levels of antifibrinolytic proteins are linked 
to a potentiated risk for intravascular thrombosis, recurrent thrombosis and thrombolytic 
failure.
7,8,10,11
 Antifibrinolytic proteins, such as TAFI and PAI-1, have been extensively studied as drug 
targets in thrombosis-related pathologies.
13
 Notwithstanding promising results, these studies 
altogether do not conclusively proclaim that inhibition of one antifibrinolytic constituent is sufficient 
to overcome thrombosis.
31,37,38
 Since TAFI and PAI-1 have complementary roles that are localized at 
the fibrin surface, we hypothesized that simultaneous targeting of the two antifibrinolytics would 
amplify the profibrinolytic capacity in a fibrin localized manner. Fibrinolysis is driven by enzymatic 
activation of plasminogen into active plasmin through the exposure of C-terminal lysines subsequent 
to plasmin-mediated cleavage of fibrin.
4
 Since these C-terminal lysines serve as co-factors for tPA-
mediated activation of plasminogen, this results in a self-propagating dissolution of fibrin. Through 
the enzymatic removal of C-terminal lysines from fibrin, TAFIa thereby confines fibrinolysis. TAFIa, 
however, prevents fibrinolysis from entering into the propagation phase only when above a certain 
threshold concentration which is proportionate to the level of plasmin activity, i.e. a higher level of 
plasmin generation requires a higher amount of generated TAFIa to withhold fibrinolysis. In terms of 
a profibrinolytic strategy, a PAI-1 inhibitor leads to an increased t-PA activity resulting in more 
plasmin generation and therefore causing an elevated threshold concentration of TAFIa. The latter in 
combination with a TAFI inhibitor results in a strong profibrinolytic effect, i.e. fibrinolysis occurs in 
the presence of much lower concentrations of t-PA. 
To facilitate drug development a two-in-one molecule was designed, called a diabody, to target TAFI 
and PAI-1 simultaneously. An additional advantage of such diabody construct was previously 
exemplified in vitro  with Db-T12D11x33H1F7
39
 and Db-TCK26D6x33H1F7.
22
 Db-TCK26D6x33H1F7 
was specifically generated for the species cross-reactive properties of the parental antibodies: 
besides its cross-reactivity towards human TAFI and human PAI-1 allowing its potential clinical use, 
the diabody can also be evaluated in preclinical studies (without the need of a surrogate diabody). In 
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both in vitro studies, the diabodies were more efficient in increasing fibrinolysis than the combined 
use of the corresponding parental antibodies. The increased in vitro potency is most likely the 
consequence of the smaller (58 kDa) and more flexible structure of a diabody, favoring efficient 
penetration and diffusion into the blood clot. The current study describes the first use of such 
profibrinolytic strategy in vivo. Db-TCK26D6x33H1F7 was first applied thromboprophylactically in a 
well-established mouse model of thromboplastin-induced thromboembolism in which a low dose of 
0.8 mg/kg (resulting in an equimolar plasma concentration of TAFI) was maximally effective in 
clearing fibrin from lungs (Figure 1).  
A common phenomenon in stroke patients is secondary infarct growth despite initial vessel 
recanalization. The precise mechanisms of this so called ‘reperfusion injury’ are still not completely 
understood but involve complex thrombo-inflammatory processes. Intravascular fibrin deposition, 
trapping erythrocytes, leukocytes and platelets have shown to directly obstruct cerebral 
microvascular perfusion during ischemia and reperfusion.
40-43
 To further assess the potential 
profibrinolytic effect of the diabody in this setting, it was evaluated in a mechanical tMCAo model of 
cerebral ischemia/reperfusion injury. The diabody prominently reduced fibrin(ogen) deposition and 
lesion volume, which was associated with improved neurological and motor outcome at 24 h (Figure 
2). In line with this observation, TAFI and PAI-1 levels are increased in patients suffering from 
ischemic stroke, often correlating with stroke severity, suggesting a negative impact of these anti-
fibrinolytic molecules in stroke development.
8,44-50
 Interestingly, whereas the diabody ameliorated 
the outcome in this model, tPA has a controversial effect, potentially through aggravating neuronal 
damage after focal cerebral ischemia.
51
 As a control, an in vitro neurotoxicity assay was performed 
with or without N-methyl-D-aspartate (NMDA) and demonstrated the absence of any neurotoxicity 
associated with the diabody (Supplemental figure S4).   
Because there is an unmet clinical need to optimize current thrombolytic treatment of acute 
ischemic stroke, we next focused on mouse models of thrombotic MCAo. Current treatment of acute 
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ischemic stroke consists of a high dose of tPA which is only effective within 4.5 h after symptom 
onset, however only 20% of the small number of patients which arrive in time receive thrombolytic 
therapy.
2,3
 This reluctance against thrombolysis stems from life-threatening side effects (hemorrhagic 
transformation and possible neurotoxicity of tPA) while the thrombus resolving efficiency of tPA is 
rather low.
52,53
 Unexpectedly, neuroprotective agents, which block molecular elaboration of ischemic 
insult on brain cells, have shown no clinical benefit in patients despite their preclinical efficacy.
54
 
Since recanalization of the occluded vessel is in essence associated with improved clinical outcome,
1
 
it makes sense to target proteins, such as TAFI and PAI-1, that inhibit thrombolysis.
11
 Indeed, when 
the diabody (0.8 mg/kg) was administered early after thrombin-mediated MCAo, a strong beneficial 
effect on lesion volume was observed (Figures 3A). This reduction of lesion volume even exceeded 
the effect of a high systemic dose of tPA (10 mg/kg). To the best of our knowledge, this is the first 
report of a pharmacological treatment of fibrin-rich clots resulting in a more efficient lysis than with 
systemic administration of plasminogen activators.  
According to a meta-analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials, the greatest benefit 
is observed if tPA treatment is initiated within 90 min post stroke onset.
36
 At 90 min post stroke onset 
and onwards, tPA treatment does not always result in a beneficial outcome, presumably because of 
the increased stability of the clot (i.e. clot retraction) resulting in thrombolytic resistance, the 
neurotoxic effect of tPA to the progressively damaged brain and/or the increased risk for 
hemorrhagic transformation. Therefore in the current study, 90 min post occlusion was tested in the 
thrombin-mediated MCAo model (Figure 3B). In contrast to the earlier treatment time point (i.e. 20 
min post occlusion), tPA treatment nor diabody treatment at 90 min post occlusion had a beneficial 
effect on the lesion volumes. Interestingly, the combined treatment of the diabody and tPA resulted 
in a significantly decreased lesion volume, underscoring the potential clinical benefit of adding the 
diabody to current thrombolytic treatment. Furthermore, a later treatment time point of 4 h post 
occlusion was tested at which tPA has previously been established to have a deleterious effect (i.e. 
increased lesion volume). In our hands, however, we only observed a tendency towards increased 
  14
lesion volumes after tPA treatment, alone or with diabody (Figure 3C). Diabody treatment at this 
time point did not have any effect, which is in line with the spontaneous resolution of the thrombin-
induced clot in this model.
55
 In correspondence to the in vitro neurotoxicity data (Supplemental 
figure S4), the diabody also had no deleterious effect in vivo. 
To address another clinically relevant issue in the thrombolytic treatment of stroke, a FeCl
3
-induced 
MCAo model was used in which platelet-rich clots are formed that are resistant to tPA. The presence 
of resistant platelet-rich clots contributes to the failure of thrombolytic therapy in the majority of 
patients.
52,53
 Thus, in this model, tPA does not reduce the lesion volume nor does it improve 
recanalization, even when administered early i.e. 20 min post occlusion.
29
 In clinical practice, cerebral 
blood flow (CBF) is often measured during and early after tPA administration to evaluate the success 
of tPA-mediated thrombolysis.
56
 For this reason in this model, CBF of the MCA was monitored by 
Laser Doppler flowmetry up to 1 h after stroke onset in this set of experiments. In addition, 
recanalization of the MCA was determined by MRA at 24 h. As expected no increase in either CBF or 
recanalization rate was observed with vehicle or exogenous tPA, whereas the diabody (at 1.6 mg/kg 
and 3.6 mg/kg) effectuated a slight, but significant increase of CBF at 1 h which further led to an 
increased recanalization rate at 24 h (Supplemental figure S3). Although no difference was detected 
between both dosages of diabody in terms of CBF and recanalization rate, only the higher dose was 
able to decrease lesion volumes.  
Bleeding is a feared complication of thrombolysis, especially in the cerebral circulation. In the 
thrombosis-induced stroke models no cerebral bleeding was observed by MRI. However, these 
models are not suitable for excluding possible cerebral bleeding, since even after tPA administration 
no hemorrhagic transformations occurred. Cerebral bleeding tendency is related to the lesion 
volume, which is relatively small in these models. The monofilament however blocks the whole MCA-
perfused territory, which typically yields large lesions and more easily transforms into cerebral 
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bleeding. In this model, rtPA has been previously demonstrated to increase the incidence of bleeding 
and oedema
57
, whereas the diabody in this study did not. 
To study the risk of systemic bleeding upon traumatic injury, we performed a tail bleeding model in 
which tPA and diabody were compared (Figure 4). A similar prolongation of bleeding time upon 
administration of tPA was observed as in a previous study.
58
 The diabody however caused no 
bleeding time prolongation nor increased accumulative hemoglobin loss. This is in agreement with a 
previous study in which TAFI/PAI-1 double deficient mice showed no prolonged bleeding.
31
 With TAFI 
and PAI-1 inhibition, the endogenous tPA activity is increased. However, this most likely does not 
exceed the systemic antifibrinolytic capacity of α
2
-antiplasmin. In case of potential side effects, the 
relatively short half-life of the diabody is also advantageous. However, it is still long enough to allow 
a bolus administration to obtain sufficiently high levels for several hours.  
In conclusion, we have created a strong fibrinolytic enhancer, designated as Db-TCK26D6x33H1F7, 
with a robust in vivo performance in a variety of thrombotic and stroke mouse models. Our results 
show that the diabody has potential clinical applications in the treatment of thrombotic disorders: (i) 
prophylaxis of venous thromboembolism, (ii) treatment of brain ischemia/reperfusion injury and (iii) 
in the thrombolytic treatment of both fibrin-rich and platelet-rich clots in ischemic stroke. This novel 
profibrinolytic approach appears to be potentially safer and more effective in mouse stroke models 
than the current treatment with tPA. Based on these results, this diabody holds promise as a 
candidate for clinical studies of thrombotic disorders.   
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Figure legends 
 
Figure 1: Thromboprophylactic effect of the diabody in a model of venous 
thromboembolism 
Fibrin deposition in lungs from endotoxemic mice (n=6-10). Fibrin deposition is expressed by 
fibrinogen equivalents (µg/ml). Baseline levels were obtained by isolating lungs from healthy 
mice (n=5) without thrombotic challenge.  
The data are represented as mean ± SEM. Statistical significance is indicated by ** (p< 0.01). 
Db indicates diabody. 
 
 
Figure 2: Evaluation of the diabody (Db) in a model of cerebral ischemia (60 min) and 
reperfusion. 
(A) Representative TTC-stained brain slices; (B) lesion volume (mm
3
); (C) Bederson score; (D) 
Grip test score of mice treated with vehicle or Db (0.8 mg/kg) alone upon reperfusion (60 
min post occlusion); (E) representative immunoblots of ipsi- vs. contralateral hemispheres 
and (F) fibrin(ogen) contents in ipsilateral hemisphere (fold increase vs. contralateral 
hemisphere) of mice treated with vehicle or Db (0.8 mg/kg) upon reperfusion (60 min post 
occlusion). All parameters were measured 24 h post stroke onset. Data are represented as 
mean ± SEM (B, F) or median (C, D); n=10-12 mice/group (B, C, D); n=4 mice/group (F); *, p< 
0.05;**, p< 0.01. Db indicates diabody. 
 
Figure 3: Evaluation of the thrombolytic efficacy of the diabody (Db) on fibrin-rich clots in a 
model of thrombin-induced MCAo.  
Lesion volume (mm
3
) at 24 h post occlusion (top) and representative T2-weighted images 24 
h post occlusion (bottom) of mice treated with vehicle, tPA (10 mg/kg), Db (0.8 mg/kg) or a 
combination of Db (0.8 mg/kg) and tPA (10 mg/kg) 20 min post occlusion (A, n= 6-8), 90 min 
post occlusion (B, n= 9-10) and 240 min post occlusion (C, n= 7-9). Dotted lines delineate 
stroke lesions. Data are represented as mean ± SEM. *, p< 0.05; **, p< 0.01; ns= not 
significant. tPA indicates recombinant tissue-type plasminogen activator; Db, diabody. 
 
Figure 4: Tail bleeding time and accumulative hemoglobin loss after IV diabody, tPA or 
diabody + tPA.  
(A) Time (min) till initial cessation of tail bleeding was monitored in mice and (B) 
accumulative bleeding up to 60 min, measured as hemoglobin (g/dL) (median, n= 9-16 
mice/group; *, p< 0.05; ** p< 0.01; *** p< 0.005). tPA indicates recombinant tissue-type 
plasminogen activator; Db, diabody.  
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